The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2025
0mins
Source: NASDAQ.COM
Impact of Trump's Administration on MedTech: The return of Trump to the White House has created uncertainty for investors in the medical device industry due to actions like withdrawing from the WHO and freezing federal regulatory activities, which may hinder innovation and complicate regulatory processes.
Growth Opportunities in Health IT and Telemedicine: Despite the challenges, sectors such as health IT, telemedicine, and digital health are expected to thrive, with companies like Doximity, Omnicell, Embecta Corp., and Cencora poised for growth under new administrative policies.
Analyst Views on EMBC
About EMBC
Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








